Whanin Pharm (016580.KS)
Whan In Pharm Co.,Ltd. manufactures and sells various pharmaceuticals products in South Korea. The company offers anti-depressants, anti-psychotics, nootropics and anti-dementia, anti-epileptics, cardiovascular, gastrointestinal, antibiotics, antiviral agents, antihistamines, anti-inflammatory and analgesics, metabolic disorders, respiratory, central nervous system, other drug products. The company was founded in 1978 and is headquartered in Seoul, South Korea.
Company Info
Highlights
₩180.00B
₩258.19B
₩89.80B
₩10,530.00 - ₩15,507.08
₩21,000.00
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
Loading data...
Returns By Period
Whanin Pharm (016580.KS) returned -0.17% year-to-date (YTD) and -16.51% over the past 12 months. Over the past 10 years, 016580.KS returned -4.79% annually, underperforming the S&P 500 benchmark at 10.85%.
016580.KS
-0.17%
0.51%
-0.91%
-16.51%
-10.40%
-0.74%
-4.79%
^GSPC (Benchmark)
0.51%
5.49%
-2.00%
12.02%
12.68%
14.19%
10.85%
Monthly Returns
The table below presents the monthly returns of 016580.KS, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | -0.25% | -2.55% | -2.96% | 5.30% | 0.51% | -0.17% | |||||||
| 2024 | -4.26% | -0.97% | 1.96% | -2.75% | 2.40% | -0.07% | -0.62% | -5.77% | -1.40% | 1.05% | -9.63% | -0.74% | -19.49% |
| 2023 | -0.57% | -1.89% | -4.83% | -1.04% | -0.62% | -8.59% | -7.15% | 7.77% | -5.31% | 0.93% | -0.50% | 9.79% | -12.79% |
| 2022 | -7.02% | 1.51% | 7.74% | 0.28% | -3.86% | -7.45% | 6.19% | -0.29% | -2.05% | 2.69% | 2.03% | 2.03% | 0.60% |
| 2021 | 9.88% | 4.09% | -5.76% | 16.39% | 4.53% | 3.65% | -5.73% | -8.88% | -4.36% | -3.75% | -6.41% | 7.78% | 8.43% |
| 2020 | -2.59% | -10.96% | 10.07% | 0.34% | -8.78% | 6.67% | 6.25% | 3.27% | -4.43% | -4.30% | 11.07% | 5.98% | 10.09% |
| 2019 | 1.04% | -3.62% | -3.49% | 7.22% | -5.44% | -3.56% | -6.82% | -7.93% | 4.64% | 3.80% | -0.30% | -3.64% | -17.73% |
| 2018 | 10.34% | 0.81% | 0.81% | -13.23% | 1.15% | -4.57% | 0.72% | 5.46% | -3.60% | -20.56% | 17.35% | -2.42% | -12.51% |
| 2017 | -5.36% | -1.67% | 6.78% | 9.52% | 1.16% | 3.72% | 9.12% | 11.39% | -2.73% | -2.80% | 15.38% | -6.00% | 42.34% |
| 2016 | 3.84% | -19.70% | -2.15% | 1.57% | 8.02% | -7.71% | 0.00% | -0.31% | -3.73% | -5.81% | 2.74% | 7.36% | -17.63% |
| 2015 | -14.78% | 8.42% | 5.88% | -4.22% | 2.09% | 5.23% | 5.40% | -5.12% | -11.45% | 0.98% | 0.72% | -4.94% | -13.83% |
| 2014 | 17.62% | 2.02% | -0.40% | 17.53% | 3.05% | 1.32% | -1.30% | 6.58% | 32.72% | 14.42% | -8.94% | 3.87% | 121.59% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of 016580.KS is 18, meaning it’s performing worse than 82% of other stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Whanin Pharm (016580.KS) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Loading data...
Dividends
Dividend History
Whanin Pharm provided a 2.54% dividend yield over the last twelve months, with an annual payout of ₩300.00 per share. The company has been increasing its dividends for 22 consecutive years.
| Period | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend | ₩300.00 | ₩300.00 | ₩300.00 | ₩300.00 | ₩300.00 | ₩300.00 | ₩300.00 | ₩300.00 | ₩300.00 | ₩250.00 | ₩250.00 | ₩250.00 |
Dividend yield | 2.54% | 2.54% | 1.99% | 1.70% | 1.69% | 1.80% | 1.94% | 1.57% | 1.35% | 1.58% | 1.28% | 1.09% |
Monthly Dividends
The table displays the monthly dividend distributions for Whanin Pharm. The dividends shown in the table have been adjusted to account for any splits that may have occurred.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | |||||||
| 2024 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩300.00 | ₩300.00 |
| 2023 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩300.00 | ₩300.00 |
| 2022 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩300.00 | ₩300.00 |
| 2021 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩300.00 | ₩300.00 |
| 2020 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩300.00 | ₩300.00 |
| 2019 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩300.00 | ₩300.00 |
| 2018 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩300.00 | ₩300.00 |
| 2017 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩300.00 | ₩300.00 |
| 2016 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩250.00 | ₩250.00 |
| 2015 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩250.00 | ₩250.00 |
| 2014 | ₩250.00 | ₩250.00 |
Dividend Yield & Payout
Dividend Yield
Whanin Pharm has a dividend yield of 2.54%, which is quite average when compared to the overall market.
Payout Ratio
Whanin Pharm has a payout ratio of 23.57%, which is quite average when compared to the overall market. This suggests that Whanin Pharm strikes a balance between reinvesting profits for growth and paying dividends to shareholders.
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading data...
Worst Drawdowns
The table below displays the maximum drawdowns of the Whanin Pharm. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Whanin Pharm was 82.14%, occurring on Jun 16, 1998. Recovery took 471 trading sessions.
The current Whanin Pharm drawdown is 50.44%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -82.14% | Sep 18, 1997 | 181 | Jun 16, 1998 | 471 | May 12, 2000 | 652 |
| -66.77% | May 15, 2000 | 76 | Aug 31, 2000 | 1088 | Feb 14, 2005 | 1164 |
| -60.56% | Apr 10, 2018 | 479 | Mar 23, 2020 | — | — | — |
| -47.38% | Oct 17, 2007 | 254 | Oct 27, 2008 | 682 | Jul 26, 2011 | 936 |
| -45.48% | Jul 6, 2015 | 396 | Feb 9, 2017 | 225 | Jan 12, 2018 | 621 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading data...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Whanin Pharm over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Earnings Per Share
The chart presents the Earnings Per Share (EPS) performance of Whanin Pharm, comparing actual results with analytics estimates.
Valuation
The Valuation section provides an overview of how Whanin Pharm is priced in the market compared to other companies in the Drug Manufacturers - Specialty & Generic industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for 016580.KS compared to other companies in the Drug Manufacturers - Specialty & Generic industry. 016580.KS currently has a PEG ratio of 0.0. This PEG ratio is low compared to industry peers, which could indicate the stock is undervalued relative to its expected growth.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for 016580.KS relative to other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, 016580.KS has a P/S ratio of 0.7. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for 016580.KS in comparison with other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, 016580.KS has a P/B value of 0.5. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |